Inside Biotech: Aroa Biosurgery's Symphony improves diabetic foot ulcer healing in US clinical trial...

Inside Biotech: Aroa Biosurgery's Symphony improves diabetic foot ulcer healing in US clinical trial Aroa Biosurgery Ltd (ASX:ARX, OTC:AROAF) has reported positive results from a US randomised controlled trial showing its Symphony wound care product significantly improved healing outcomes for diabetic foot ulcers when added to standard care. The prospective multicentre study enrolled 143 patients across 10 US sites and found 55% of diabetic foot ulcers treated with Symphony plus standard care achieved complete wound closure within 12 weeks, compared with 35% for patients receiving standard care alone.